QuickView: First human lipid biomarker trends
Early data in healthy volunteers have demonstrated trends in favour of AEM-28 on a number of lipid biomarkers, even at low doses. These are the first-in-man data, which hint at potential future efficacy. AEM-28 continues to be investigated in a Phase Ib/IIa trial, with data anticipated by YE14/Q115. These could pave the way for future development in an orphan cardiovascular indication, although additional funds will likely be needed if data are positive.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.